- Home
- NSSC vs MYGN Comparison
NSSC vs MYGN Comparison
Compare NSSC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSSC
- MYGN
- Stock Information
- Founded
- NSSC 1969
- MYGN 1991
- Country
- NSSC United States
- MYGN United States
- Employees
- NSSC N/A
- MYGN N/A
- Industry
- NSSC Telecommunications Equipment
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NSSC Telecommunications
- MYGN Health Care
- Exchange
- NSSC Nasdaq
- MYGN Nasdaq
- Market Cap
- NSSC 899.1M
- MYGN 744.7M
- IPO Year
- NSSC N/A
- MYGN 1995
- Fundamental
- Price
- NSSC $27.35
- MYGN $4.92
- Analyst Decision
- NSSC Strong Buy
- MYGN Hold
- Analyst Count
- NSSC 4
- MYGN 15
- Target Price
- NSSC $33.75
- MYGN $15.14
- AVG Volume (30 Days)
- NSSC 346.4K
- MYGN 2.2M
- Earning Date
- NSSC 05-05-2025
- MYGN 08-05-2025
- Dividend Yield
- NSSC 2.06%
- MYGN N/A
- EPS Growth
- NSSC N/A
- MYGN N/A
- EPS
- NSSC 1.22
- MYGN N/A
- Revenue
- NSSC $181,227,000.00
- MYGN $831,300,000.00
- Revenue This Year
- NSSC N/A
- MYGN N/A
- Revenue Next Year
- NSSC $6.02
- MYGN $6.68
- P/E Ratio
- NSSC $22.41
- MYGN N/A
- Revenue Growth
- NSSC N/A
- MYGN 7.38
- 52 Week Low
- NSSC $19.00
- MYGN $3.81
- 52 Week High
- NSSC $58.09
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- NSSC 46.55
- MYGN 46.03
- Support Level
- NSSC $27.56
- MYGN $4.78
- Resistance Level
- NSSC $29.17
- MYGN $5.29
- Average True Range (ATR)
- NSSC 0.74
- MYGN 0.32
- MACD
- NSSC -0.25
- MYGN 0.11
- Stochastic Oscillator
- NSSC 32.85
- MYGN 60.98
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.